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What’s onco-nephro?
Acute renal failure 
• Pre-renal 
• Volume depletion
• Vomiting, diarrhea, sepsis
• Meds: diuretics, NSAIDs, ACE, ARB, etc.
• Hypercalcemia- natriuresis and vasoconstriction
• PTH related protein production-promotes liberation of Ca from bone
• SCC of lung, cervix, and esophagus, lymphomas, RCC, and adenocarcinoma of 
breast, prostate, ovary
• Bone metastases- mobilize Ca and osteoclasts
• Myeloma, breast and lung metastases
• Expression of 1-alpha hydroxylase leading to conversion of 25-OH vit D to calcitriol
• Hodgkin’s and Non-Hodgkin’s
• Treatment- Volume, Bisphosphonates, Donosumab, rarely steroids
Acute renal failure
•Pre-renal (cont.)
• Hepatic Sinsusoidal Obstruction Syndrome
• Complication of hematopoietic cell transplantation (HCT)
• Acute radiochemotherapy induced damage to sinusoidal hepatocytes 
leading to thrombosis and portal hypertension
• Similar physiology to hepato-renal but 70% will recover with 
supportive care
• Calcineurin inhibitors
• Used in prevention of GVHD, e.g. tacrolimus, cyclcosporine
• Can cause both dose dependent AKI and CKD
Acute renal failure
• Intrinsic
• Glomerular (paraneoplastic syndromes)
• Membranous GN(GVHD, solid tumor malignancy)
• 5-25% related to malignancy
• Can be idiopathic or malignancy associated, in 2009 Beck et al found 
circulating PLA2R Ab in those w idiopathic disease; 75% of those w 
idiopathic disease are +….remaining need age-appropriate cancer 
screening
• Minimal Change Disease (hematologic malignancies)
• IgA nephropathy (RCC)
• FSGS, HSP, ANCA vasculitis, AA amyloid (more studies needed to illustrate 
relationship)
• Lymphomatous infiltration of the kidney
Acute renal failure
• Intrinsic
• Tubulointerstitial
• Cast Nephropathy (15-40% of myeloma pts), requiring acute dialysis at 
diagnosis (10%)
• Survival significantly shorter in those with renal failure
• Clonal free light chains overwhelm the proximal tubule so they 
continue to the distal tubule where they bind to Tamm Horsefall
protein and create tubular obstruction
• Renal recovery appears to be time sensitive, prompt treatment key



Plasmapheresis
Brenner and Rector’s The 
Kidney, 8th ed. 2071-2080, 
2007. 
Plasmapheresis at SJMC
Acute renal failure
• Intrinsic
• Tumor lysis syndrome
• Occurs after the treatment of lg volume malignancies, usually 
hematologic, some solid tumor as well, occasionally even before 
treatment
• Occurs when intracellular contents overwhelm excretion of the body
• Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, 
hallmarks
• Uric acid is the main concern causing injury that can prolong
• Treatments include allopurinol, febuxostat and rasburicase
Acute renal failure
• Intrinsic
• Thrombotic microangiopathy
• Results from platelet activation and formation of thrombi with 
subsequent vessel wall swelling and necrosis
• Forms include cancer-associated and hematopoietic cell transplantation-
associated
Acute renal failure
• Post-renal 
• Obstruction- most common in bladder, uterine and prostate 
cancers
• Tumor obstruction
• Lymphatic obstruction
• Retroperitoneal fibrosis (radiation-induced vs malignancy itself)
• Treated with nephrostomy vs ureteral stent
Kitai Y et al. Onco-nephrology: 
Current concepts and future 
perspectives.  Japanese Journal 
of Clinical Oncology, 2015 45(7) 
617-628.
Chemotherapy in CKD
• Most chemo is renally excreted but data on renal/dialysis clearance is incomplete
• Excretion in general is of cytotoxic metabolites so delays in elimination can lead 
to toxicity/overdose
• Also chemo exacerbates chronic conditions like renal anemia, infection risks
• Glomerular filtration and hemodialysis play an important role in clearance of non-
protein bound molecules (e.g. carboplatin, can be cleared in dialysis pts if timed 
well but after 24h, protein-binding increases leading to toxicity)
• Tyrosine kinase inhibitors generally safer as cleared by the liver but still a study on 
sorafenib saw far more bleeding events in dialysis patients due to more 
vulnerable vasculature
Cancer risk in CKD
• In CKD pts impaired immune system, decreased antioxidant defense, accumulation of 
carcinogens due to impaired clearance, chronic infection and inflammation all increase 
cancer risk
• Uremic toxins also increase risk of viral mediated cancers 
• Chronic dialysis suppressed DNA repair activity of lymphocytes and also associated w 
glutathione perioxidase deficiency
• Cystic kidney diseases increase the risk of kidney cancers
• Thyroid cancers are higher during dialysis and after transplant
• CKD pts treated with cyclophosphamide, azathioprine, other immunosuppressives, all 
inc risk
• However large retrospective studies have not necessarily isolated these differences 
cancer rates in dialysis patients, possible due to reduced screening and high 
cardiovascular mortality
Screening for cancer in ESRD
• Cost per unit of survival benefit may be 20x higher in dialysis patients
• A typical screening program may have a net gain in life expectancy of 5 days or 
less amongst a dialysis cohort
• Most societies recommend continuing screening in dialysis patients for those on a 
transplant waiting list but age cutoffs vary
• Renal cell carcinoma  is not screened for in the general population but in those on 
dialysis 3 years or more aged 20 a 1.6 year survival benefit was suggested if 
screened every 3 years
Screening for cancer post transplantation
Holley, J.  Cancer screening in ESRD. Onco-nephrology curriculum. 
American Society of Nephrology, 2016.
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